Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053652 | 0.80 | FFAR2 (0.68) | FFAR2LMNAKMT2ACYP2D6HDAC1 | |
| SCHEMBL29054565 | 0.80 | CYP2D6 (0.61) | LMNAKMT2ACYP2D6CTSDSMN1; SMN2 | |
| SCHEMBL6342212 | 0.78 | LMNA (0.46) | FFAR2LMNAKMT2ACYP2D6HDAC1 | |
| SCHEMBL6162357 | 0.77 | LMNA (0.51) | LMNAKMT2AHDAC1HDAC3HDAC8 | |
| SCHEMBL9055207 | 0.77 | LMNA (0.51) | LMNAKMT2AHDAC1HDAC3HDAC8 | |
| SCHEMBL6039993 | 0.74 | LMNA (0.53) | FFAR2LMNAKMT2AHDAC1HDAC3 | |
| SCHEMBL6837072 | 0.74 | KMT2A (0.50) | FFAR2LMNAKMT2ACYP2D6CTSD | |
| Dimethylamine SCHEMBL7053166 | 0.73 | LMNA (0.43) | LMNAKMT2ACYP2D6HDAC1HDAC3 | |
| SCHEMBL7391810 | 0.73 | ALOX5 (0.47) | LMNAKMT2ACYP2D6ALDH1A1 | |
| SCHEMBL8927802 | 0.72 | EPHX1 (0.46) | LMNACYP2D6HDAC1HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1426356-B1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MIRTAZAPINE AND THE PRODUCTION METHODS THEREOF | MEDICHEM SA (ES) | 2008-04-16 | — | — | EP | claimed |
| US-7265223-B2 | Intermediate compounds for the preparation of mirtazapine and production methods thereof | MEDICHEM, S.A. (ES) | 2007-09-04 | — | — | US | claimed |
| US-20040236107-A1 | Intermediate compounds for the preparation of mirtazapine and the production methods thereof | MEDICHEM, S.A. (ES) | 2004-11-25 | — | — | US | claimed |
| EP-1426356-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MIRTAZAPINE AND THE PRODUCTION METHODS THEREOF | Medichem S.A. (ES) | 2004-06-09 | — | — | EP | claimed |
| EP-1426356-B1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MIRTAZAPINE AND THE PRODUCTION METHODS THEREOF | MEDICHEM SA (ES) | 2008-04-16 | — | — | EP | disclosed |
| US-7265223-B2 | Intermediate compounds for the preparation of mirtazapine and production methods thereof | MEDICHEM, S.A. (ES) | 2007-09-04 | — | — | US | disclosed |
| US-20040236107-A1 | Intermediate compounds for the preparation of mirtazapine and the production methods thereof | MEDICHEM, S.A. (ES) | 2004-11-25 | — | — | US | disclosed |
| EP-1426356-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MIRTAZAPINE AND THE PRODUCTION METHODS THEREOF | Medichem S.A. (ES) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236107-A1 | Intermediate compounds for the preparation of mirtazapine and the production methods thereof | IMPDH1, MRM1, IMPDH2 | FFAR2 4071/4885LMNA 491/4885KMT2A 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.